Who are Raunormin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Austedo, Xenazine, Moderil, Vyvanse, Ingrezza.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/deserpidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Raunormin — Competitive Intelligence Brief

Raunormin (DESERPIDINE) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Catecholamine-depleting Sympatholytic. Area: Cardiovascular.

marketed Catecholamine-depleting Sympatholytic Synaptic vesicular amine transporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Raunormin (DESERPIDINE).

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Raunormin TARGET	DESERPIDINE		marketed	Catecholamine-depleting Sympatholytic	Synaptic vesicular amine transporter	1957-01-01
Austedo	DEUTETRABENAZINE	Teva	marketed		Synaptic vesicular amine transporter	2017-01-01
Xenazine	TETRABENAZINE	Bausch Health	marketed	Vesicular Monoamine Transporter 2 Inhibitor [EPC]	Synaptic vesicular amine transporter	2008-01-01
Moderil	RESCINNAMINE	Pfizer	marketed	rescinnamine	Synaptic vesicular amine transporter	1956-01-01
Vyvanse	Vyvanse	Vanderbilt University	marketed		Sodium-dependent dopamine transporter, Sodium-dependent noradrenaline transporter, Synaptic vesicular amine transporter
Ingrezza	valbenazine	Neurocrine	marketed		Potassium voltage-gated channel subfamily H member 2, Synaptic vesicular amine transporter, Synaptic vesicular amine transporter

Recent regulatory actions (last 90 days)

2026-04-08 — Ingrezza · FDA · approved · US · Neurocrine

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Catecholamine-depleting Sympatholytic class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Raunormin — Competitive Intelligence Brief. https://druglandscape.com/ci/deserpidine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab